Publications by authors named "Miriam Iezza"

Claim this Profile
C
Case Report: Uncommon co-occurrence of different renal histopathological entities in a patient with multiple myeloma and lymphoplasmacytic lymphoma.
Marco Talarico, Gisella Vischini, Simona Barbato, Roberta Restuccia, Simone Masci, Miriam Iezza

Front Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic myeloid leukemia outcomes according to baseline risk and first-line treatment in real-world settings: Data from the Italian Network/CML Campus.
Valentina Giai, Tiziana Rosso, Fausto Castagnetti, Patrizia Pregno, Massimiliano Bonifacio, Miriam Iezza

Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home.
Flavia Bigi, Mauro Fiacchini, Roberta Restuccia, Simone Masci, Gaia Mazzocchetti, Miriam Iezza

Clin Exp Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia and contributes to genomic instability: SETD2 loss in Chronic Myeloid Leukemia.
Manuela Mancini, Sara De Santis, Cecilia Monaldi, Fausto Castagnetti, Miriam Iezza

Clin Transl Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients-A Systematic Review.
Flavia Bigi, Enrica Manzato, Simona Barbato, Marco Talarico, Michele Puppi, Miriam Iezza

Pharmaceuticals (Basel)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.
Olga Mulas, Elisabetta Abruzzese, Luigiana Luciano, Alessandra Iurlo, Immacolata Attolico, Miriam Iezza

Ann Hematol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic pseudoprogression in a patient with metastatic KIT exon 11 GIST after 1 month of first-line imatinib: a case report.
Elisa Tassinari, Nicole Conci, Giacomo Battisti, Francesco Porta, Valerio Di Scioscio, Miriam Iezza

Front Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights.
Miriam Iezza, Sofia Cortesi, Emanuela Ottaviani, Manuela Mancini, Claudia Venturi

Cells· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study.
Alessandra Iurlo, Daniele Cattaneo, Silvia Artuso, Dario Consonni, Elisabetta Abruzzese, Miriam Iezza

Front Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis